TET2 and pulmonary arterial hypertension: Consistent with the pathologic contribution of this inflammatory state to the development of PAH, mice with a homozygous deletion of TET2 responded therapeutically with reduced PAH to therapy with canakinumab, an IL-1β inhibitory antibody [20].